In many cancers, SHP2 mediates signal transduction from receptor tyrosine kinases to Ras, and several allosteric inhibitors of SHP2 have entered clinical trials for the treatment of receptor tyrosine kinase-driven cancers7,8. The gene discussed is NTRK1; the disease is cancer.